You just read:

Aridis Pharmaceuticals Reports Phase 2 Clinical Trial Results of AR-105 for the Treatment of Ventilator-Associated Pneumonia Caused by Pseudomonas Aeruginosa

News provided by

Aridis Pharmaceuticals, Inc.

Sep 03, 2019, 05:30 ET